Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 147616, 11 pages
http://dx.doi.org/10.1155/2015/147616
Research Article

Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis

1Department of Medicine, University of Verona, 37134 Verona, Italy
2G. Gaslini Institute, 16148 Genoa, Italy
3University of Genoa, 16126 Genoa, Italy
4Pederzoli Hospital, Peschiera del Garda, 37019 Verona, Italy

Received 19 September 2014; Revised 9 February 2015; Accepted 2 March 2015

Academic Editor: David E. Gilham

Copyright © 2015 Tinazzi Elisa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Abraham, T. Krieg, J. Distler, and O. Distler, “Overview of pathogenesis of systemic sclerosis,” Rheumatology, vol. 48, pp. iii3–iii7, 2009. View at Google Scholar · View at Scopus
  2. A. Gabrielli, E. V. Avvedimento, and T. Krieg, “Mechanisms of disease: scleroderma,” The New England Journal of Medicine, vol. 360, no. 19, pp. 1989–2003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Vancheeswaran, T. Magoulas, G. Efrat et al., “Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vasular dysfunction?” The Journal of Rheumatology, vol. 21, no. 10, pp. 1838–1844, 1994. View at Google Scholar · View at Scopus
  4. A. Kuryliszyn-Moskal, P. A. Klimiuk, and S. Sierakowski, “Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement,” Clinical Rheumatology, vol. 24, no. 2, pp. 111–116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Yamane, T. Miyauchi, N. Suzuki et al., “Significance of plasma endothelin-1 levels in patients with systemic sclerosis,” Journal of Rheumatology, vol. 19, no. 10, pp. 1566–1571, 1992. View at Google Scholar · View at Scopus
  6. D. Abraham and O. Distler, “How does endothelial cell injury start? The role of endothelin in systemic sclerosis,” Arthritis Research and Therapy, vol. 9, no. 2, article S2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. R. Levin, “Endothelins,” The New England Journal of Medicine, vol. 333, pp. 356–363, 1995. View at Google Scholar
  8. A.-K. Khimji and D. C. Rockey, “Endothelin-biology and disease,” Cellular Signalling, vol. 22, no. 11, pp. 1615–1625, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Shi-Wen, F. Rodríguez-Pascual, S. Lamas et al., “Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors,” Molecular and Cellular Biology, vol. 26, no. 14, pp. 5518–5527, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Finsnes, T. Lyberg, G. Christensen, and O. H. SkjØnsberg, “Effect of endothelin antagonism on the production of cytokines in eosinophilic airway inflammation,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 280, no. 4, pp. L659–L665, 2001. View at Google Scholar · View at Scopus
  11. U. R. Juergens, K. Racké, S. Uen et al., “Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: new evidence for beneficial anti-inflammatory potency of ETB-receptor antagonism,” Pulmonary Pharmacology and Therapeutics, vol. 21, no. 3, pp. 533–539, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Iwata, S. Ito, M. Iwaki et al., “Regulation of endothelin-1-induced interleukin-6 production by Ca2+ influx in human airway smooth muscle cells,” European Journal of Pharmacology, vol. 605, no. 1–3, pp. 15–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. H. Sprague and R. A. Khalil, “Inflammatory cytokines in vascular dysfunction and vascular disease,” Biochemical Pharmacology, vol. 78, no. 6, pp. 539–552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Sutcliffe, D. L. Clarke, D. A. Bradbury, L. M. Corbett, J. A. Patel, and A. J. Knox, “Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NF-kappaB and AP-1,” British Journal of Pharmacology, vol. 157, no. 3, pp. 436–450, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Shephard, B. Hinz, S. Smola-Hess, J.-J. Meister, T. Krieg, and H. Smola, “Dissecting the roles of endothelin, TGF-beta and GM-CSF on myofibroblast differentiation by keratinocytes,” Thrombosis and Haemostasis, vol. 92, no. 2, pp. 262–274, 2004. View at Google Scholar · View at Scopus
  16. G. M. Rubanyi and M. A. Polokoff, “Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology,” Pharmacological Reviews, vol. 46, no. 3, pp. 325–335, 1994. View at Google Scholar · View at Scopus
  17. A. Yatawara, J. L. Wilson, L. Taylor, P. Polgar, and D. F. Mierke, “C-terminus of ETA/ETB receptors regulate endothelin-1 signal transmission,” Journal of Peptide Science, vol. 19, pp. 257–262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. C. Verhaar, F. E. Strachan, D. E. Newby et al., “Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade,” Circulation, vol. 97, no. 8, pp. 752–756, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Clozel and G. A. Gray, “Are there different ETB receptors mediating constriction and relaxation?” Journal of Cardiovascular Pharmacology, vol. 26, no. 3, pp. S262–S264, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. J. K. Dammanahalli and Z. Sun, “Endothelin (ET)-1 inhibits nicotinamide adenine dinucleotide phosphate oxidase activity in human abdominal aortic endothelial cells: a novel function of ETB1 receptors,” Endocrinology, vol. 149, no. 10, pp. 4979–4987, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. S. Ahmedat, M. Warnken, W. K. Seemann et al., “Pro-fibrotic processes in human lung fibroblasts are driven by an autocrine/paracrine endothelinergic system,” British Journal of Pharmacology, vol. 168, no. 2, pp. 471–487, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Shi-Wen, C. P. Denton, M. R. Dashwood et al., “Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1,” Journal of Investigative Dermatology, vol. 116, no. 3, pp. 417–425, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Shi-Wen, S. L. Howat, E. A. Renzoni et al., “Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK,” The Journal of Biological Chemistry, vol. 279, no. 22, pp. 23098–23103, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. X. Shiwen, A. Leask, D. J. Abraham, and C. Fonseca, “Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma,” European Journal of Clinical Investigation, vol. 39, no. 2, pp. 19–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Shi-Wen, E. A. Renzoni, L. Kennedy et al., “Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts,” Matrix Biology, vol. 26, no. 8, pp. 625–632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Shi-Wen, Y. Chen, C. P. Denton et al., “Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts,” Molecular Biology of the Cell, vol. 15, no. 6, pp. 2707–2719, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Saleh and D. M. Pollock, “Endothelin in renal inflammation and hypertension,” Contributions to Nephrology, vol. 172, pp. 160–170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. D. E. Kohan and M. Barton, “Endothelin and endothelin antagonists in chronic kidney disease,” Kidney International, vol. 86, pp. 896–904, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. C.-M. Weng, B.-C. Chen, C.-H. Wang et al., “The endothelin a receptor mediates fibrocyte differentiation in chronic obstructive asthma the involvement of connective tissue growth factor,” American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 3, pp. 298–308, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. T. B. Coyle and M. L. Metersky, “The effect of the endothelin-1 receptor antagonist, bosentan, on patients with poorly controlled asthma: a 17-week, double-blind, placebo-controlled crossover pilot study,” Journal of Asthma, vol. 50, no. 4, pp. 433–437, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. M. E. Yeager, D. D. Belchenko, C. M. Nguyen, K. L. Colvin, D. D. Ivy, and K. R. Stenmark, “Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 46, no. 1, pp. 14–22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Mencarelli, A. Pecorelli, P. Carbotti, G. Valacchi, G. Grasso, and M. Muscettola, “Endothelin receptor A expression in human inflammatory cells,” Regulatory Peptides, vol. 158, no. 1–3, pp. 1–5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. D. E. Kohan, J. G. Cleland, L. J. Rubin, D. Theodorescu, and M. Barton, “Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?” Life Sciences, vol. 91, no. 13-14, pp. 528–539, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Hachulla and J. G. Coghlan, “A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism,” Annals of the Rheumatic Diseases, vol. 63, no. 9, pp. 1009–1014, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J. D. Croxtall and S. J. Keam, “Ambrisentan,” Drugs, vol. 68, no. 15, pp. 2195–2204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Matucci-Cerinic, C. P. Denton, D. E. Furst et al., “Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial,” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 32–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. M. E. Hettema, D. Zhang, H. Bootsma, and C. G. M. Kallenberg, “Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 66, no. 10, pp. 1398–1399, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Shetty and C. T. Derk, “Endothelin receptor antagonists as disease modifiers in systemic sclerosis,” Inflammation and Allergy—Drug Targets, vol. 10, no. 1, pp. 19–26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. G. K. Karavolias, P. Georgiadou, A. Gkouziouta et al., “Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses,” Expert Opinion on Therapeutic Targets, vol. 14, no. 12, pp. 1283–1289, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Iannone, M. T. Riccardi, S. Guiducci et al., “Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension,” Annals of the Rheumatic Diseases, vol. 67, no. 8, pp. 1121–1126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Balbir-Gurman and Y. Braun-Moscovici, “Scleroderma—new aspects in pathogenesis and treatment,” Best Practice and Research: Clinical Rheumatology, vol. 26, no. 1, pp. 13–24, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. F. van den Hoogen, D. Khanna, J. Fransen et al., “2013 classification criteria for systemic sclerosis: an american college of rheumatology/European league against rheumatism collaborative initiative,” Arthritis & Rheumatism, vol. 65, no. 11, pp. 2737–2747, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. F. van den Hoogen, D. Khanna, J. Fransen et al., “2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative,” Annals of the Rheumatic Diseases, vol. 72, no. 11, pp. 1747–1755, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Kowalczyk, P. Kleniewska, M. Kolodziejczyk, B. Skibska, and A. Goraca, “The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis,” Archivum Immunologiae et Therapiae Experimentalis, vol. 63, no. 1, pp. 41–52, 2015. View at Publisher · View at Google Scholar
  45. M. Manetti, S. Guiducci, E. Romano et al., “Differential expression of junctional adhesion molecules in different stages of systemic sclerosis,” Arthritis and Rheumatism, vol. 65, no. 1, pp. 247–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Raghu, J. Behr, K. K. Brown et al., “Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, Randomized Trial,” Annals of Internal Medicine, vol. 158, no. 9, pp. 641–649, 2013. View at Publisher · View at Google Scholar · View at Scopus